Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reparixin - Dompe Farmaceutici

Next Previous
Drug Profile

Reparixin - Dompe Farmaceutici

Alternative Names: DF-1681Y; Repertaxin; Repertaxin L-Lysine salt

Latest Information Update: 20 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dompe Farmaceutici
  • Developer Dompe Farmaceutici; Fox Chase Cancer Center; Icahn School of Medicine at Mount Sinai; SatRx; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Benzeneacetamides; Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; COVID-19 pneumonia; Delayed graft function
  • Phase II Adult respiratory distress syndrome; Essential thrombocythaemia; Fatigue; Liver transplant rejection; Myelofibrosis; Polycythaemia vera; Triple negative breast cancer
  • No development reported Breast cancer
  • Discontinued Cerebral ischaemia

Most Recent Events

  • 11 Dec 2024 Dompé Farmaceutici terminates a phase II trial in Liver transplant rejection (Prevention) in Russia, Belarus (IV) according to the Protocol and the DMC conclusion(NCT03031470)
  • 27 Sep 2024 Dompé Farmaceutici terminates phase-III trial in COVID-19 pneumonia (Adjunctive treatment) and Community-acquired pneumonia (Adjunctive treatment) in Argentina, Australia, Turkey, Italy, Austria, Germany, and USA (PO) due to futility (NCT05254990)
  • 27 Jun 2023 Phase-II clinical trials in Essential thrombocythaemia (Treatment-experienced) in USA (PO) (NCT05835466)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top